SLRX Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 mai 2024 @ 22:00):

Stats
Dagens volum	97 751.00
Gjennomsnittsvolum	111 890
Markedsverdi	2.52M
EPS	$0 ( 2024-03-25 )
Neste inntjeningsdato	( $-6.70 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.140
ATR14	$0.0110 (2.08%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-11	Arthur David J.	Buy	20 500	Stock Option (right to buy)
2024-02-20	Rosenblum Mark J	Buy	22 500	Stock Option (right to buy)
2024-02-20	Mcvicar William K.	Buy	20 500	Stock Option (right to buy)
2024-02-20	Mccreedy Bruce J Jr.	Buy	20 500	Stock Option (right to buy)
2024-02-20	Lieber Jonathan I	Buy	20 500	Stock Option (right to buy)

INSIDER POWER
100.00
Last 99 transactions
Buy: 2 809 420 \| Sell: 0

Salarius Pharmaceuticals Korrelasjon

10 Mest positive korrelasjoner
OTLY	0.838
TCON	0.807

10 Mest negative korrelasjoner
BNIXU	-0.818

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Salarius Pharmaceuticals Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-10 051.00 (0.00 %)
EPS:	$-3.84

FY	2023
Omsetning:	$0
Bruttogevinst:	$-10 051.00 (0.00 %)
EPS:	$-3.84

FY	2022
Omsetning:	$0
Bruttogevinst:	$-6 677.00 (0.00 %)
EPS:	$-14.77

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-7.72

Financial Reports:

No articles found.

Salarius Pharmaceuticals

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.